Interpretations of the Term “Actionable” when Discussing Genetic Test Results: What you Mean Is Not What I Heard by Gornick, Michele C. et al.
334  |   wileyonlinelibrary.com/journal/jgc4 J Genet Couns. 2019;28:334–342.© 2018 National Society of Genetic Counselors
1  | INTRODUC TION
The emergence of precision medicine, along with advances in ge‐
nomic sequencing technology, bring new diagnostic and screening 
tests and new terminology (Jarvik and Evans 2016). The medical 
terminology used by healthcare providers and researchers is often 
confusing for patients and research participants, with no clear or 
precise meaning (Clayman et al. 2016). This lack of clarity can result 
in miscommunication and make it difficult for laypersons to identify, 
let alone understand, which aspects of genetic information are rele‐
vant for healthcare decisions (Berkman et al. 2011; Shay and Lafata 
2014).
Health care providers can best communicate medical informa‐
tion to patients by using well‐defined, plain language (i.e., wording 
patients can understand the first time they read or hear it) (Centers 
for Disease Control and Prevention 2016; Fagerlin et al. 2011; Plain 
Language Association International 2016; Rudd et al. 2004) so that 
“gist knowledge” (i.e., the essential meaning of medical information) 
can be achieved (Hawley et al. 2008; Tait et al. 2010). The concept 
of gist understanding, or the processes that form representations 
of an event’s meaning in language or logic rather than its surface 
details, arises from the fuzzy‐trace theory that draws upon the dual 
process theory of memory (Gomes and Brainerd 2012; Reyna and 
Brainerd 1995). However, commonly used words or phrases do not 
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In genomic medicine, the familiarity and inexactness of the term “actionable” can 
lead to multiple interpretations and mistaken beliefs about realistic treatment 
options. As part of a larger study focusing on public attitudes toward policies for the 
return of secondary genomic results, we looked at how members of the lay public 
interpret the term “medically actionable” in the context of genetic testing. We also 
surveyed a convenience sample of oncologists as part of a separate study and asked 
them to define the term “medically actionable.” After being provided with a definition 
of the term, 21 out of 60 (35%) layperson respondents wrote an additional action not 
specified in the provided definition (12 mentioned “cure” and 9 mentioned 
environment or behavioral change) and 17 (28%) indicated “something can be done” 
with no action specified. In contrast, 52 surveyed oncologists did not mention 
environment, behavioral change, or cure. Based on our findings, we propose that 
rather than using the term “actionable” alone, providers should also say “what they 
mean” to reduce miscommunication and confusion that could negatively impact 
medical decision‐making. Lastly, to guide clinicians during patient‐ provider discussion 
about genetic test results, we provide examples of phrasing to facilitate clearer 
communication and understanding of the term “actionable.”
K E Y W O R D S
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always have the same core meaning for different users (Nickerson 
1999). When plain language terms with different potential meanings 
are used as medical jargon, this may lead to imprecise or inaccurate 
gist understanding, undermining communication between patients 
and healthcare providers, and potentially impacting decision‐making 
(Lafata et al. 2017).
Medical genetics is an area of medicine where this communica‐
tion challenge is particularly acute. Not only does genetics require 
the communication of complex concepts, but because it is a rapidly 
advancing field, genetics also introduces new, unfamiliar terms, and 
expands and alters the meaning of existing medical jargon. The term 
“actionable” (as in “clinically or medically actionable”), for example, 
is now widely used in medical genetics. “Actionable” first gained 
traction in the field of medical genetics after the 2013 release of 
the American College of Medical Genetics and Genomics (ACMG) 
recommendations on how to handle disclosure of incidental findings 
(now known as secondary findings) from clinical genomic sequencing 
(American College of Medical Genetics and Genomics 2013; Green 
et al. 2013; Kalia et al. 2017). Following the issuance of these recom‐
mendations, there was a noticeable increase in the use of the term 
“actionable”in the genetics literature as a short‐ hand, common de‐
scription of the notion that “something can be done” using results 
obtained from genetic testing (see Fig. 1).
The term “actionable” has been used in a variety of ways, including, 
but not limited to: “potentially actionable” (Bieg‐Bourne et al. 2017; 
Damodaran et al. 2015; Ferrarotto et al. 2016), “clinically actionable” 
(Desmond et al. 2015; Douglas et al. 2016; Vandekerkhove et al. 
2017), and “actionable mutation” (Butler et al. 2015; Schwaederle et 
al. 2016; Thierry et al. 2017). These articles range from guidelines, 
policy, and perspective pieces focusing on “actionability” (Berg et 
al. 2013; Carr et al. 2016; Manolio et al. 2013; Ramos et al. 2014; 
Sukhai et al. 2016; Vidwans et al. 2014) to empirical research that 
provide various, implicit, or explicit definitions of the term “action‐
able” (Ananda et al. 2015; Butler et al. 2015; Middha et al. 2014; 
Pritchard et al. 2014; Wong et al. 2015; Wyatt et al. 2016; Yuan et al. 
2016). There are also differences in how geneticists define the term 
“actionable” as evident from the lack of full consensus over what 
genes should be considered actionable and routinely disclosed when 
genomic sequencing is done (Green et al. 2012).
In its simplest form, actionable means “capable of being acted 
on” (Merriam‐Webster 2018). It implies one can “do something,” but 
gives little indication of the scope (what actions and how many?), 
quality (to what effect/outcome?), or availability (how likely?) of the 
action. Different users of the term (i.e., laboratory scientists, health‐
care providers in the clinic, patients, and insurers) use it to convey 
a wide range of concepts. For example, in the context of genetic 
testing, laboratories reporting results use the term to describe a 
broad range of potential provider recommendations, including “re‐
ferral to genetic counseling” or “genetic counseling is recommended” 
(O’Daniel et al. 2017). In the clinic, healthcare providers may use the 
term to indicate anything from the availability of screening based on 
a genetic test result to a newly available clinical trial to evaluate a 
potential therapy based on a specific gene mutation (Biesecker and 
Green 2014; Green et al. 2016). This expansive use of the term “ac‐
tionable” in genetics can muddle the core message of this seemingly 
plain language term.
This combination of familiarity and lack of precision can lead to 
multiple interpretations, resulting in misunderstanding and miscom‐
munication between genetics laboratories, clinicians, and patients. 
This disconnect can potentially increase the risk of harm to patients. 
Harm can occur in many ways, for example, in cases where the term 
“actionable” leads patients to believe that more can be done for their 
condition than is realistically possible (e.g., distress, depression, anx‐
iety, disappointment, hopelessness) (Zikmund‐Fisher 2017), or diffi‐
culties in trying to enumerate all possible terms in larger domains like 
“disease” (e.g., congestive heart failure could be considered a disease 
or diagnostic finding) (Cimino 1993). Given the widespread usage of 
this term in medicine and the potential for misunderstanding, we 
collected preliminary evidence regarding how the term “action‐
able” is defined and understood by both patients and providers, and 
whether different user interpretations of the term have implications 
for incorporating genomic information into clinical management. As 
part of a larger study focusing on public attitudes toward policies for 
the return of secondary genomic results (Gornick et al. 2017; Ryan 
F I G U R E  1   Number of journal articles 
that referred to actionable/actionability 
as it relates to human genomics/genetics 
(n = 1252). Search terms used in PubMed 
(through December 31, 2017) listed in 
supplemental table. Further exclusions: 
reference type: book, comment; 
actionable/actionability not in title/
abstract; actionability not used in direct 
relation to genomic or genetic results, 
non‐human genetics

















2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
336  |     GORNICK et al.
et al. 2017), we looked at how members of the lay public interpret 
the term “medically actionable” in the context of genetic testing. We 
also surveyed a convenience sample of oncologists as part of a sepa‐
rate study and asked them to define the term “medically actionable.”
2  | METHODS
2.1 | Lay Persons’ Interpretation of the Term 
“Medically Actionable”
A detailed description of the study’s theoretical basis, research 
design, and methodological procedures are described elsewhere 
(Gornick et al. 2017). Briefly, 66 individuals with and without a 
personal history of cancer were recruited through the University 
of Michigan Clinical Studies website, a voluntary partnership 
created for researchers to list studies and patients and community 
members to find studies that they are interested in participating 
[https://UMClinicalStudies.org]. This website is a secure, password‐
protected recruitment portal. Study teams provide basic information 
about their studies including, purpose, eligibility, what participation 
involves, and contact information. Potential volunteers visit the 
website and can sign up for a specific study or for a general registry. 
From this convenience sample, individuals who expressed interest in 
the study were asked a series of screening questions on age, gender, 
ethnicity, and personal history of cancer to ensure diversity both in 
sample characteristics and diversity in participant’s health status. 
Participants had to be at least 21 years old to participate (Table 1).
Selected individuals were invited to participate in an all‐day 
deliberative democracy (DD) session on policies for the return of 
secondary genomic sequencing findings. During the expert presen‐
tations at the DD session, the term “medically actionable” was de‐
fined as: “Results that show a DNA change that increases your risk 
for health conditions that can be prevented, screened for, reduced 
or treated.” At the end of the DD session, participants were given a 
survey that included the definition of a “medically actionable” result 
that was expanded and listed in bullet form as follows: (1) A change 
in a person’s DNA that increases the risk of developing a specific 
health condition. (2) A medical result where actions can be taken 
to prevent, screen, reduce, or treat symptoms of the health condi‐
tion. (3) Examples: certain types of heart conditions (e.g., high risk 
of heart attack), cancers (e.g., colon, breast, prostate), neurological 
conditions (e.g., Parkinson’s disease). Participants were then asked 
“In your own words, when you hear the term “medically actionable,” 
what does it mean to you?” Text responses (N = 60) were analyzed 
using qualitative coding (i.e., content analysis) for key themes. This 
coding scheme was developed by study team members based on a 
literature review of the term “medically actionable” and refined using 
an iterative method (i.e., after categorical codes were developed, 
new codes were added as needed). Any discrepancies were resolved 
by group discussion. Responses were coded by types of “actions” 
mentioned (i.e., treatment, lifestyle change) and categorized by how 
closely the “actions” corresponded with the study team definition. 
Responses that did not include any specific, precise actions were 
categorized as either “medical action” (e.g., rephrasing of the term 
“medically actionable”) or “something can be done” (does not specify 
if it is a “medical action” or lifestyle change) responses. Finally, we 
had a separate category for incorrect or off‐topic responses.
2.2 | Clinicians’ Interpretation of the Term 
“Medically Actionable”
In a separate pilot study of a genomic test report prototype, a 
convenience sample of all medical oncologists, radiation oncologists, 
and hematologists practicing in the state of Michigan identified 
TA B L E  1   Participant demographics




Age, mean (SD) 57.3 (14)
Ethnicity “mark all that apply”
White 50 (78.1)
Black 11 (17.2)
American Indian or Alaskan Native 4 (6.3)
Asian 2 (3.1)
Hispanic 2 (3.1)
Middle Eastern/Arab 1 (1.6)
Other 1 (1.6)
Education
High school or less 4 (6.3)
Some college/college/trade school 33 (51.6)
Graduate degree 26 (40.6)
Annual household income
Below $40,000 16 (25.0)
$40,000–$79,999 28 (43.8)
More than $80,000 17 (27.0)








Academic medical center 31 (60)
Private practice 13 (25)
Community hospital 8 (15)
Number of patients per week
> 20 patients/week 26 (50)
aIncluded are all participants who attended DD session and responded to 
all three surveys bSome percentages do not add to 100 because not all 
participants answered the question 
     |  337GORNICK et al.
through the Michigan Society of Hematology and Oncology mailing 
list was invited to participate. Oncologists were informed that the 
study was part of a quality assurance and improvement project of a 
genomic sequencing results report. Participation was voluntary, and 
all survey responses de‐identified. A questionnaire and a postage‐
paid return envelope was provided. On the survey, participants 
were asked, “In your own words, when you hear the term “medically 
actionable,” what does it mean to you?”
3  | RESULTS
3.1 | Lay Persons’ Interpretation of the Term 
“Medically Actionable”
No respondent provided all parts of the study team definition. 
However, nearly all respondents (N = 58; 96.7%) provided a basic 
or “gist” meaning of the term “medically actionable.” This included 
respondents who provided one or more parts of the study team def‐
initions, used a specific, other action not mentioned in the provided 
definition, and/or used an imprecise definition (e.g., “something can 
be done”). Although the vast majority of respondents had a “gist” 
understanding of “medically actionable,” the actual content of defi‐
nitions varied. Two‐thirds (N = 40; 66.7%) of respondents used at 
least one part of the definition we provided, e.g., “Medically action‐
able means that a disease or disability can be treated to the point of 
a positive outcome” (ID‐01). One‐third (N = 20; 33.3%) of respond‐
ents used two parts of the study team’s definitions, e.g., “Medical 
diagnosis that can be treated and/or prevented” (ID‐21) (Table 2).
Over one‐third of the respondents (N = 21; 35%) wrote in an ad‐
ditional action that was not specified in the study team’s definition. 
Nine of these participants included a non‐medical (e.g., lifestyle or 
environmental) action in their definition. For example, one partici‐
pant wrote: “I can do something to prevent/treat the disease; either 
by diet, environment or medicine” (ID‐60). Several (N = 12; 20%) 
TA B L E  2   In your own words, when you hear the term “medically actionable”, what does it mean to you? (N = 60)
Response code Response code description Responses n%
Uses complete provided definition
Uses or rephrases definition provided by study team: “… actions can be taken to treat, 
prevent, delay, or reduce symptoms of the health condition” Uses all key terms, or clear 
synonyms of the terms: “treat,” “prevent,” and (delay OR reduce) in answer
0 (0.0%)
Uses 2 parts of provided definition
Mentions two of the key terms related to treatment, prevention, or qualitative change (like 
“delay” or “reduce”)
20 (33.3%)
Uses 1 part of provided definition
Mentions one of the key terms related to treatment, prevention, or qualitative change (like 
“delay” or “reduce”)
40 (66.7%)
Treatment Treat part of definition mentioned (synonym: therapy, medication, 
therapeutic)
25 (41.7%)
Prevention Prevent part of definition mentioned (synonym: avoid, screen) 19 (31.7%)
Delay or reduce Either mentions “delay” or “reduce” (or synonyms that suggest a 
qualitative change: mitigate, lessen, alleviate, keep from 
progressing, improve, decease, slow down)
16 (26.7%)
Uses a specific action 
NOT mentioned in 
definition
21 (35.0%)
Cure Uses term cure/curable (or synonym: eliminate, correct) 12 (20.0%)
Lifestyle change Uses term lifestyle change of life decision, including diet, 
environmental, or behavior change (NOT changes medically nor 
non‐specified types of changes)
9 (15.0%)
Uses a vague definition 17 (28.3%)
Medical action (general) Uses or rephrases the term “medically actionable.” Does not use any 
of the key terms (or synonyms) in provided definition. May instead 
use “action” synonyms: influence, intervention, effect, change, 
alter (not qualitative like improve, lessen)
9 (15.0%)
Something can be done General statement that an action can be taken/something can be 
done, but does not specify if it is medical or lifestyle action. Does 
not use any of the key terms (or synonyms) in provided definition
8 (13.3%)
Gives incorrect or 
off‐topic response
The response is either off‐topic, incorrect, or unclear. 2 (3.3%)
Note. Not all participants answered the question
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participants mentioned “cure” or “curable” as part of their definition, 
e.g., “I think it means a medical condition that can be cured or at least 
lessened” (ID‐36).
In addition, 17 (28.3%) of participants used phrasings such as 
“something can be done” or “something medical can be done” but 
did not specify the type of action to be performed. For example, one 
participant stated: “Something could be done about the problem” 
(ID‐41). Another wrote in: “Action available to medically influence a 
condition” (ID‐03).
Finally, respondents provided different combinations of types 
of actions in their definitions. One participant wrote in: “Something 
can be done medically to reduce the risk of developing a disease, 
obtaining screening earlier, also a change in lifestyle choices!” (ID‐11) 
Another wrote: “There are certain illnesses/conditions that can be 
treated or delayed or cured in some fashion” (ID‐19).
3.2 | Clinicians’ Interpretation of the Term 
“Medically Actionable”
Unlike members of the public, clinician survey respondents (N = 52; 
71% male; 73% self‐reported as white; 50% reported seeing ≥ 20 
patients/week; 60% reported practicing at an academic medical 
center, 25% in private practice, 15% in a community hospital 
setting) almost never provided vague type “something can be done” 
answers, though some were vague in action, such as “It means that 
there is either a treatment or referral that could take place” (ID‐120). 
Clinicians also did not give any responses that included patient 
behavior, environmental change, or the possibility of a cure.
Often, clinicians gave very precise or detailed definitions. For ex‐
ample, one clinician provided a comprehensive list of what the term in‐
cludes: “(1) Known germline susceptibility, NOT [variants of unknown 
significance], that lead to proven strategies, (screening, prophylactic 
surgery, other prevention strategies), (2) Known somatic changes 
that lead to standard of care for THAT disease (e.g., ER+ or HER2+, 
mBRCA), (3) Known somatic changes that lead to standard of care with 
other diseases, might be considered for different disease (e.g., ER+ in 
lung cancer) “off label,” (4) known somatic changes that make [patient] 
eligible for clinical trial of investigational drug (as in [Molecular Analysis 
for Therapy Choice]) or [standard of care] drug in different disease ( as 
in [Targeted Agent and Profiling Utilization Registry])” (ID‐114).
Another oncologist focused on the clinical indication (in this con‐
text, a patient’s current cancer), “Implies there is a somatic mutation 
within the tumor for which there may be a drug that may affect an 
anti‐cancer effect” (ID‐116).
Several clinicians included additional types of actions that were 
NOT mentioned by the public, including family implications, genetic 
counseling, merely making decisions, or “no” action as an action. 
Finally, some clinicians emphasized uncertainty of benefit and a few 
also mentioned the challenge of access (e.g., nearness of clinical 
trial). For example, “That there is a clinical intervention to offer the 
patient, that can treat the cancer and that I can write an Rx for with‐
out having to refer every patient to a tertiary center. Many patients 
can’t travel.”
4  | DISCUSSION
4.1 | So What Does it all Mean?
As genomic medicine expands in both the research and clinical 
arenas, determining whether, how, and which findings to return to the 
clinician and patient becomes increasingly important. Several studies 
report the use of an a priori categorization of genes, using the concept 
of actionability in order to facilitate informed consent, analysis, and 
return of results (Berg et al. 2013; Shirts et al. 2015). Our data indicate 
that while laypersons generally have a good gist understanding of the 
term “actionable,” their definition of “medically actionable” varies, 
even after both being provided a definition verbally in a presentation 
and in written form right above the question that asked for their 
definition. We found that clinicians also have a good understanding 
of the core meaning of “actionable,” yet it is quite different from the 
understanding of the lay public. Many clinicians offered very precise 
and detailed definitions, and most of their definitions focused on 
“treatment and/or delay/reduce symptoms” through the use of 
medications or clinical trials. Very few clinicians used the vague type 
answers provided by laypersons (i.e., “something can be done”), and 
no clinicians mentioned cure or lifestyle change.
Overall, our preliminary data provides evidence to support the 
idea that when a familiar, plain language word that is also used as med‐
ical jargon has multiple gist meanings, different groups (e.g., medical 
professionals vs. lay members of the public) may impute their group‐
specific interpretations to the term, potentially without realizing that 
other audiences have different understandings of the same word. In 
this report, we provide pilot evidence suggesting that there is a lack 
of shared meaning of “medically actionable,” which may contribute to 
doctor‐patient miscommunication and interfere with informed medi‐
cal decision‐making. This creates a situation where patients could ex‐
perience the disappointment of unmet expectations, confusion, and a 
lack of appreciation of both the range of specific actions and multiple 
actions that may need to be taken. For example, after diagnosis of a 
condition like heredity cardiomyopathy, actions might include medi‐
cation for control of blood pressure, screening to monitor the heart, 
diet and exercise to improve heart function, or a more invasive proce‐
dure such as an implantable defibrillator.
Given that the term “medically actionable” has a range of spe‐
cific and multiple meanings, as well as different gist interpretations 
by the various users (i.e., researchers, clinicians, and patients), we 
propose that rather than just using the term “actionable,” health 
care providers should also say “what they mean” to reduce mis‐
communication and confusion between health care providers and 
patients that could negatively impact medical decision‐making and 
trust. Discordance in interpretation can undermine patient trust. 
Given the longitudinal nature of the patient‐provider relationship, 
particular challenges for facilitating trust exist since uncertainty 
about future related and unrelated medical interactions are un‐
known. Therefore, special attention should be taken to address 
cultural values and communication barriers, and integrate patient 
expectations (Kraft et al. 2018).
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It is important to “say what you mean” (Astor 2011; Cimino 1993; 
Fantry 2016). In order to guide clinicians during patient‐provider dis‐
cussion about genetic test results, we have set out a list of suggested 
phrases (see Table 3).
We also believe that there are also situations where the term 
“medically actionable” needs additional clarification. For example, 
referring to the availability of a clinical trial or off‐label use of an 
FDA‐approved drug as “medically actionable” may lead to patient 
misunderstandings about distinctions between research and clinical 
care.
Clarity in “what you mean” is essential in the “no stone un‐
turned”/“there is nothing we can do” category. This describes the 
situation when genetic testing may be done, even though the antici‐
pated yield of a positive result is low, in order to not miss a potential 
diagnosis for which there could be a treatment. In this context, test‐
ing is being used to determine that nothing more can be done, and 
it needs to be made clear to the patient that doing this testing might 
be a “last resort” option. For example, clinicians may order whole 
exome sequencing when all previous genetic testing, including panel 
testing, has been negative.
This report has some limitations. First, due to the convenience 
sample recruitment strategy, both clinician and lay person respon‐
dents were necessarily self‐selected and thus unrepresentative of 
the general population. Also, clinician and citizen responses were 
gathered as part of separate surveys in which a study team definition 
of medically actionable was provided to lay persons but not clini‐
cians, which may in turn have had a differential impact on responses 
to the “medical actionability” question. Despite these limitations, we 
feel that our findings are suggestive of a communication challenge 
that merits consideration and that caution should be taken with 
phrasing when “actionable” is used in laboratories reporting clinical 
results and in healthcare.
The lack of shared meaning of “medically actionable,”—which 
may contribute to doctor‐patient miscommunication and interfere 
with informed medical decision‐making—is a resolvable challenge. 
Confusion regarding medical terminology and challenges in relaying 
risk information can be addressed through both patient and clinician 
education. When conveying medically actionable information, asking 
the patient or research participant to state back their understanding 
can help the healthcare provider or researcher determine whether 
TA B L E  3   Suggested phrasing for clinicians to use with the term “medically actionable”
Type of action Description Suggested language
Screening By “medically actionable,” I mean that…
Patient screening Imaging or screening of patient for a disease 
or disorder
…you should get regular screening (e.g., imaging of your heart to 
screen for hypertrophic cardiomyopathy).
Family screening Genetic testing of relatives (cascade 
screening) for a disease or disorder
…your at‐risk family members (e.g. siblings) can be tested to see 
if the gene change for [specify name of condition] has been 
inherited (e.g. patient with a family history of malignant 
hyperthermia).
Treatment
Treatment avoidance Not having a treatment or therapy that may 
be potentially harmful
…you should avoid… (e.g., certain types of anesthesia and instead 
use safer alternatives during surgery [patients with malignant 
hyperthermia]).
Additional treatment Having an additional therapy or treatment 
that may be potentially helpful
…you could… (e.g., take a beta‐blocker medication, which will 
reduce your risk for heart problems [patients with hypertrophic 
cardiomyopathy]).
Surgical options
Insertion Having surgery to insert/implant something 
that may be potentially helpful
…you could have surgery to insert… (e.g., a defibrillator in or near 
your heart to reduce your risk of a heart attack [patients with 
hypertrophic cardiomyopathy]).
Removal Having procedure/surgery to remove 
something that may be potentially affected
…you could have surgery to remove… (e.g., the colon to 
significantly reduce your risk for colon cancer [patients with 
familial adenomatous polyposis]).
Behavior
Diet Changing diet to reduce health risks or 
symptoms
…you could change your diet by… (e.g., eating less fatty food and 
eating more foods with fiber to reduce your risk for heart 
problems [patients with familial hypercholesterolemia]).
Activities/exercise Doing activities to reduce health risks or 
symptoms
…you should exercise regularly… (e.g., to lower your cholesterol 
levels and reduce your risk for heart problems [patients with 
familial hypercholesterolemia]).
Avoiding activities Avoid certain types of activities/exercise to 
reduce health risks or symptoms
…you should avoid… (e.g., contact sports and choose safer 
alternatives such as swimming to reduce your risk for heart 
problems [patients with Marfan syndrome]).
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the information has been effectively conveyed or when additional 
explanation is needed. Further studies are necessary to examine 
patient reactions to a clinician using the phrasing “By medically ac‐
tionable, I mean…” and assess changes in comprehension. Many of 
the challenges discussed here can be resolved by taking the time to 
communicate medically actionable information in a deliberate, direct, 
clear, and concise way.
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